产品分类导航
Esomeprazole sodium API (under development)
Esomeprazole sodium API (under development)
Esomeprazole sodium API (under development)

Esomeprazole sodium API (under development)

更新时间:2025-02-07

价格:
CAS号: 161796-78-7
药典: 中国药典,企业标准
级别: Medicine Grade
立即询盘
收藏

产品详情

产品名称: Esomeprazole sodium API (under development)
产品分类: 消化系统用药
CAS号: 161796-78-7
药典: 中国药典,企业标准
级别: Medicine Grade
主要销售市场: 北美洲,中/南美洲,西欧,东欧,亚洲,中东,非洲
是否提供样品:

产品描述:

Category: API

Usage: It is used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome.

Applications: Pharmaceutical raw materials

Place of Origin: China

Quality Specification: Please contact Baiyu for updated version COA

公司简介

四川宏明博思药业有限公司成立于2013年,专注于原料药和制剂的生产。现有员工400余人,主要生产高端剂型如注射剂、冻干粉针剂、片剂和胶囊剂。宏明博思的冻干粉针制剂生产线已获得EU GMP,并通过巴西ANVISA现场检查。目前四川宏明博思冻干粉针制剂的多个产品在巴西、智利、秘鲁、危地马拉、泰国、菲律宾、马来西亚、南非、澳大利亚等开展注册中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
注册资本:
企业规模(人):
业务类型:
成立日期:
年销售额:
主营产品类别:
四川宏明博思药业有限公司
注册资本不愿意公开
公司地址
四川省成都市成都高新区合作路343号
联系人
查看联系方式
快速询盘
询盘主题
请输入询盘主题
询盘信息
请输入询盘信息
快速发送询盘
2006-2026 上海博华国际展览有限公司版权所有(保留一切权利) 沪ICP备05034851号-57